Search

Your search keyword '"Chiang, Cho Hung"' showing total 149 results
Start Over Author "Chiang, Cho Hung"
149 results on '"Chiang, Cho Hung"'

2. Rate of Sodium Correction and Osmotic Demyelination Syndrome in Severe Hyponatremia: A Meta-Analysis

Author

See Xin Ya, Chang Yu-Cheng, Peng Chun-Yu, Wang Shih-Syuan, Chi Kuan-Yu, Chiang Cho-Hung, and Chiang Cho-Han

Subjects
hyponatremia, rapid correction, osmotic demyelination syndrome, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
Abstract

Current guidelines recommend limiting the rate of correction in patients with severe hyponatremia to avoid severe neurologic complications such as osmotic demyelination syndrome (ODS). However, published data have been conflicting. We aimed to evaluate the association between rapid sodium correction and ODS in patients with severe hyponatremia.

Published
2024
Full Text
View/download PDF

13. Abstract 12767: Sodium-Glucose Cotransporter-2 Inhibitors Are Associated With Lower Risks of Hospitalization for Heart Failure and All-Cause Mortality in Patients With Diabetes Mellitus and Cancer

Author

Chiang, Cho Han, CHIANG, CHO HUNG, Chiang, Cho Hsien, Ma, Kevin, Peng, Chun-Yu, yuanping, HSIA, Horng, Chuan-Sheng, CHEN, CHENG-YING, Chang, Yu-Cheng, See, Xin Ya, Chen, Yuan-Jen, Wang, Shih-Syuan, Suero Abreu, Giselle A, Peterson, Linda R, Thavendiranathan, Paaladinesh, Armand, Philippe, Peng, Cheng-Ming, Shiah, Her-Shyong, and Neilan, Tomas G

Published
2022
Full Text
View/download PDF

15. The comparative efficacy and safety of factor Xa inhibitors and warfarin for primary thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy.

Author

Chang, Yu‐Cheng, Song, Junmin, Chi, Kuan‐Yu, Gao, Wenli, Chang, Yu, Chiang, Cho‐Hung, Hsia, Yuan Ping, and Chiang, Cho‐Han

Subjects
VENOUS thrombosis, MULTIPLE myeloma, SAFETY factor in engineering, WARFARIN, GASTROINTESTINAL hemorrhage
Abstract

Summary: There are limited data on the optimal choice of anticoagulation in multiple myeloma (MM) patients receiving immunomodulatory drugs (IMiDs). We conducted a propensity score‐matched cohort study using the TriNetX database to compare the efficacy and safety of factor Xa inhibitors and warfarin in this patient population. Compared to warfarin, factor Xa inhibitors had a similar risk of deep vein thrombosis (hazard ratio [HR]: 1.11 [95% CI: 0.50–2.46]) or pulmonary embolism (HR: 1.08 [95% CI: 0.59–2.00]). There were no differences in the risk of gastrointestinal or intracranial bleeding. Factor Xa inhibitor‐treated patients had lower all‐cause mortality (HR: 0.56 [95% CI: 0.36–0.86]) compared with warfarin. These data suggest that factor Xa inhibitors had similar safety and efficacy compared with warfarin for MM patients on IMiDs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. The Effect of Exercise on Cardiotoxicity in Women with Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Systematic Review and Meta-Analysis.

Author

Chiang, Cho-Han, Chang, Yu-Cheng, Haw, Yulin, Tan, Jia Yi, Chiang, Cho-Hsien, Hsia, Yuan Ping, and Chiang, Cho-Hung

Subjects
EXERCISE physiology, MEDICAL information storage & retrieval systems, WOMEN, VENTRICULAR ejection fraction, EXERCISE therapy, BREAST tumors, TREATMENT effectiveness, META-analysis, DESCRIPTIVE statistics, CANCER chemotherapy, SYSTEMATIC reviews, MEDLINE, CARDIAC output, RESISTANCE training, CARDIOTOXICITY, ANTHRACYCLINES, MEDICAL databases, AEROBIC exercises, ONLINE information services, OXYGEN consumption, CONFIDENCE intervals, GLOBAL longitudinal strain
Abstract

Introduction: Breast cancer is the most common cancer in women with a 5-year survival over 90%. However, anthracycline-based chemotherapy causes significant cardiotoxicity often requiring discontinuation of chemotherapeutic regimen among breast cancer survivors. We conducted a systematic review and meta-analysis to evaluate the efficacy of exercise training in mitigating anthracycline-related cardiotoxicity among women with breast cancer. Methods: We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus databases. The outcomes of interest were left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), early to atrial filling velocity (E/A) ratio, maximal oxygen consumption (VO2 max), and cardiac output (CO). We used the Cochrane risk-of-bias tool for randomized trials (RoB 2) to assess the risk of bias in individual studies. Results: We identified a total of 596 articles with 5 trials included in the final analysis. Exercise training was associated with an increase in VO2 max compared with no exercise training (mean difference, 3.95 [95% CI, 0.63–7.26]; I2 = 99.68%). Other cardiovascular outcomes such as LVEF (mean difference, 1.76 [95% CI, −1.95 to 5.46]; I2 = 99.44%), GLS (mean difference, 0.30 [95% CI, −0.49 to 1.10]; I2 = 96.63%), E/A ratio (mean difference, 0.05 [95% CI, −0.05 to 0.15]; I2 = 94.16%), and CO (mean difference, 0.38 [95% CI, −0.91 to 1.66]; I2 = 99.73%) are similar between patients who underwent exercise training and those who did not. Conclusions: Exercise was associated with an improvement in maximal oxygen uptake among women with breast cancer receiving anthracycline-based chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. The impact of sodium‐glucose cotransporter‐2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer

Author

Chiang, Cho‐Han, primary, Chiang, Cho‐Hung, additional, Hsia, Yuan Ping, additional, Jaroenlapnopparat, Aunchalee, additional, Horng, Chuan‐Sheng, additional, Wong, Kit Yee, additional, Wang, Shih‐Syuan, additional, Chang, Yu‐Cheng, additional, Chen, Brian Shiian, additional, Luan, Yu‐Ze, additional, Wang, Chun‐Hao, additional, Neilan, Tomas G., additional, Chiang, Cho‐Hsien, additional, Peng, Cheng‐Ming, additional, and Shiah, Her‐Shyong, additional

Published
2024
Full Text
View/download PDF

18. Impact of different corticosteroids on severe community-acquired pneumonia: a systematic review and meta-analysis

Author

See, Xin Ya, primary, Wang, Tsu Hsien, additional, Chang, Yu-Cheng, additional, Lo, Juien, additional, Liu, Weitao, additional, Choo, Cheryn Yu Wei, additional, Lee, Yu-Che, additional, Ma, Kevin Sheng Kai, additional, Chiang, Cho-Hsien, additional, Hsia, Yuan Ping, additional, Chiang, Cho-Hung, additional, and Chiang, Cho-Han, additional

Published
2024
Full Text
View/download PDF

24. Efficacy of Lipophilic Statins on Outcomes of Patients Treated with Immune Checkpoint Inhibitors.

Author

Chiang, Cho-Han, Chen, Yuan-Jen, See, Xin Ya, Chang, Yu-Cheng, Wang, Shih-Syuan, Peng, Chun-Yu, Horng, Chuan-Sheng, Hsia, Yuan Ping, Chiang, Cho-Hung, Peng, Cheng-Ming, and Chiang, Cho-Hsien

Subjects
STATINS (Cardiovascular agents), DRUG efficacy, DISEASE progression, IMMUNE checkpoint inhibitors, ANTILIPEMIC agents, ACADEMIC medical centers, MORTALITY, RETROSPECTIVE studies, TREATMENT effectiveness, DESCRIPTIVE statistics, PROGRESSION-free survival, DATA analysis software, HEPATOCELLULAR carcinoma, IMMUNOTHERAPY, LONGITUDINAL method, OVERALL survival, PROPORTIONAL hazards models, EVALUATION
Abstract

Background: Statins are associated with improved survival outcomes in patients receiving immune checkpoint inhibitors (ICIs), but the impact of lipophilic and hydrophilic statin properties on patient outcomes is unknown. Objectives: We aim to investigate if statins with lipophilic properties are associated with clinical outcomes in patients receiving ICIs. Method: We conducted a retrospective cohort study at two tertiary referral centers in Taiwan comprising patients receiving ICIs between January 2015 and December 2021. We compared the comparative effect of lipophilic and hydrophilic statins on patient outcomes. The primary outcome was overall survival (OS) and the secondary outcome was progression-free survival (PFS). Results: Among 734 patients receiving ICIs, there were 51 lipophilic statin users, 25 hydrophilic statin users, and 658 nonusers. Lipophilic statin users had a longer median OS (38.0 [IQR, 16.7–not reached] vs. 15.2 [IQR, 8.2–not reached] months vs. 18.9 [IQR, 5.4 51.6] months) and PFS (13.0 [IQR, 4.7–41.5] vs. 8.2 [IQR, 2.2–14.7] months vs. 5.6 [2.3–18.7] months) than hydrophilic statin users and non-statin users. In Cox proportional hazard analyses, the use of lipophilic statins was associated with a 40–50% lower risk of mortality and disease progression compared with hydrophilic statin or non-statin users. Conclusions: The use of lipophilic statins seems to be associated with survival benefits in patients undergoing immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. The impact of peroxisome proliferator‐activated receptor‐γ activating angiotensin receptor blocker on outcomes of patients receiving immunotherapy

Author

Chiang, Cho‐Han, primary, Chang, Yu‐Cheng, additional, Wang, Shih‐Syuan, additional, Chen, Yuan‐Jen, additional, See, Xin Ya, additional, Peng, Chun‐Yu, additional, Hsia, Yuan Ping, additional, Chiang, Cho‐Hsien, additional, Chiang, Cho‐Hung, additional, and Peng, Cheng‐Ming, additional

Published
2023
Full Text
View/download PDF

26. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer

Author

Chiang, Cho-Han, primary, Chiang, Cho-Hung, additional, Chiang, Cho-Hsien, additional, Ma, Kevin Sheng-Kai, additional, Peng, Chun-Yu, additional, Hsia, Yuan Ping, additional, Horng, Chuan-Sheng, additional, Chen, Cheng-Ying, additional, Chang, Yu-Cheng, additional, See, Xin Ya, additional, Chen, Yuan-Jen, additional, Wang, Shih-Syuan, additional, Suero-Abreu, Giselle A, additional, Peterson, LR, additional, Thavendiranathan, Paaladinesh, additional, Armand, Philippe, additional, Peng, Cheng-Ming, additional, Shiah, Her-Shyong, additional, and Neilan, Tomas G, additional

Published
2022
Full Text
View/download PDF

27. The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations

Author

Chiang, Cho-Han, primary, Chiang, Cho-Hung, additional, Ma, Kevin Sheng-Kai, additional, Hsia, Yuan Ping, additional, Lee, Yu-wen, additional, Wu, Han-Ru, additional, Chiang, Cho-Hsien, additional, Peng, Chun-Yu, additional, Wei, James Cheng-Chung, additional, Shiah, Her-Shyong, additional, Peng, Cheng-Ming, additional, and Neilan, Tomas G, additional

Published
2022
Full Text
View/download PDF

28. Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors

Author

Chiang, Cho-Han, primary, Chiang, Cho-Hung, additional, Peng, Chun-Yu, additional, Hsia, Yuan Ping, additional, See, Xin Ya, additional, Horng, Chuan-Sheng, additional, Chang, Yu-Cheng, additional, Shen, Xuan-Er, additional, Wang, Shih-Syuan, additional, Tsai, Tien-Chi, additional, Chen, Yuan-Jen, additional, Ma, Kevin Sheng-Kai, additional, Chen, Brian Shiian, additional, Luan, Yu-Ze, additional, Tay, Soon-Tzeh, additional, Shen, Chin-Hsuan, additional, Chung, Katharine Ching, additional, Chiang, Cho-Hsien, additional, and Peng, Cheng-Ming, additional

Published
2022
Full Text
View/download PDF

34. Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction

Author

Chiang, Cho-Han, primary, Chiang, Cho-Hung, additional, Pickering, John W., additional, Stoyanov, Kiril M., additional, Chew, Derek P., additional, Neumann, Johannes T., additional, Ojeda, Francisco, additional, Sörensen, Nils A., additional, Su, Ke-Ying, additional, Kavsak, Peter, additional, Worster, Andrew, additional, Inoue, Kenji, additional, Johannessen, Tonje R., additional, Atar, Dan, additional, Amann, Michael, additional, Hochholzer, Willibald, additional, Mokhtari, Arash, additional, Ekelund, Ulf, additional, Twerenbold, Raphael, additional, Mueller, Christian, additional, Bahrmann, Philipp, additional, Buttinger, Nicolas, additional, Dooley, Maureen, additional, Ruangsomboon, Onlak, additional, Nowak, Richard M., additional, DeFilippi, Christopher R., additional, Peacock, William F., additional, Neilan, Tomas G., additional, Liu, Michael A., additional, Hsu, Wan-Ting, additional, Lee, Gin Hoong, additional, Tang, Pui-Un, additional, Ma, Kevin Sheng-Kai, additional, Westermann, Dirk, additional, Blankenberg, Stefan, additional, Giannitsis, Evangelos, additional, Than, Martin P., additional, and Lee, Chien-Chang, additional

Published
2022
Full Text
View/download PDF

37. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer

Author

Chiang, Cho-Han, Chiang, Cho-Hung, Chiang, Cho-Hsien, Ma, Kevin Sheng-Kai, Peng, Chun-Yu, Hsia, Yuan Ping, Horng, Chuan-Sheng, Chen, Cheng-Ying, Chang, Yu-Cheng, See, Xin Ya, Chen, Yuan-Jen, Wang, Shih-Syuan, Suero-Abreu, Giselle A, Peterson, LR, Thavendiranathan, Paaladinesh, Armand, Philippe, Peng, Cheng-Ming, Shiah, Her-Shyong, and Neilan, Tomas G

Abstract

ObjectivesSodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce heart failure (HF) in at-risk patients and may possess antitumour effects. We examined the effect of SGLT2i on HF and mortality among patients with cancer and diabetes.MethodsThis was a retrospective propensity score-matched cohort study involving adult patients with type 2 diabetes mellitus diagnosed with cancer between January 2010 and December 2021. The primary outcomes were hospitalisation for incident HF and all-cause mortality. The secondary outcomes were serious adverse events associated with SGLT2i.ResultsFrom a total of 8640 patients, 878 SGLT2i recipients were matched to non-recipients. During a median follow-up of 18.8 months, SGLT2i recipients had a threefold lower rate of hospitalisation for incident HF compared with non-SGLT2i recipients (2.92 vs 8.95 per 1000 patient-years, p=0.018). In Cox regression and competing regression models, SGLT2i were associated with a 72% reduction in the risk of hospitalisation for HF (HR 0.28 (95% CI: 0.11 to 0.77), p=0.013; subdistribution HR 0.32 (95% CI: 0.12 to 0.84), p=0.021). The use of SGLT2i was also associated with a higher overall survival (85.3% vs 63.0% at 2 years, p<0.001). The risk of serious adverse events such as hypoglycaemia and sepsis was similar between the two groups.ConclusionsThe use of SGLT2i was associated with a lower rate of incident HF and prolonged overall survival in patients with cancer with diabetes mellitus.

Published
2023
Full Text
View/download PDF

39. The Practice of Wearing Surgical Masks during the COVID-19 Pandemic

Author

Chiang, Cho-Han, Chiang, Cho-Hung, Chiang, Cho-Hsien, and Chen, Yee-Chun

Subjects
Epidemics -- Health aspects, Influenza -- Health aspects, Health
Abstract

To the Editor: We read with interest the metaanalysis conducted by Xiao et al. (1) that found no significant reduction in influenza transmission with the use of surgical masks in [...]

Published
2020

46. Safety and efficacy of the European Society of Cardiology 0/1-hour algorithm for diagnosis of myocardial infarction: systematic review and meta-analysis.

Author

Cho-Han Chiang, Cho-Hung Chiang, Gin Hoong Lee, Weng-Tein Gi, Yuan-Kun Wu, Sih-Shiang Huang, Yee Hui Yeo, Giannitsis, Evangelos, Chien-Chang Lee, Chiang, Cho-Han, Chiang, Cho-Hung, Lee, Gin Hoong, Gi, Weng-Tein, Wu, Yuan-Kun, Huang, Sih-Shiang, Yeo, Yee Hui, and Lee, Chien-Chang

Subjects
MYOCARDIAL infarction, META-analysis, CARDIOLOGY, HEART tumors, ALGORITHMS
Abstract

Objective: The European Society of Cardiology (ESC) 0/1 hour algorithm has been primarily validated in Europe, America and Australasia with less knowledge of its performance outside of these settings. We aim to evaluate the performance of the ESC 0/1 hour algorithm across different contexts.Methods: We searched PubMed, Embase, Scopus, Web of Science and the Cochrane Central Register of Controlled Trials for relevant studies published between 1 January 2008 and 31 May 2019. The primary outcome was index myocardial infarction and the secondary outcome was major adverse cardiac event or mortality. A bivariate random-effects meta-analysis was used to derive the pooled estimate of each outcome.Results: A total of 11 014 patients from 10 cohorts were analysed for the primary outcome. The algorithm based on high-sensitivity cardiac troponin (hs-cTn)T (Roche), hs-cTnI (Abbott) and hs-cTnI (Siemens) had pooled sensitivity of 98.4% (95% CI=95.1% to 99.5%), 98.1% (95% CI=94.6% to 99.3%) and 98.7% (95% CI=97.3% to 99.3%), respectively. The algorithm based on hs-cTnT (Roche) and hs-cTnI (Siemens) had pooled specificity of 91.2% (95% CI=86.0% to 94.6%) and 95.9% (95% CI=94.1% to 97.2%), respectively. Among patients in the rule-out category, the pooled mortality rate at 30 days and at 1 year was 0.1% (95% CI=0.0% to 0.4%) and 0.8% (95% CI=0.5% to 1.2%), respectively. Among patients in the observation zone, the pooled mortality rate was 0.7% (95% CI=0.3% to 1.2%) at 30 days but increased to 8.1% (95% CI=6.1% to 10.4%) at 1 year, comparable to the mortality rate in the rule-in group.Conclusion: The ESC 0/1 hour algorithm has high diagnostic accuracy but may not be sufficiently safe if the 1% miss-rate for myocardial infarction is desired.Prospero Registration Number: CRD42019142280. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results